IP Library Granted Patent US 8,202,887
Granted Patent B2
US 8,202,887 · App. 12/304,990 · Granted Jun 19, 2012

2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,202,887
App. No.
12/304,990
Granted
Jun 19, 2012
Kind
B2
Abstract

The present invention relates to 2-(substituted-amino)-benzothiazole sulfonamide compounds and derivatives, their use as protease inhibitors, in particular as broad-spectrum HIV protease inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. The present invention also concerns combinations of the present 2-(substituted-amino)-benzothiazole sulfonamide compounds and derivatives with another anti-retroviral agent. It further relates to their use in assays as reference compounds or as reagents.

Claims (12)

1. A compound having the formula (I)

a salt, stereoisomeric form or stereoisomeric form thereof wherein

R is a piperidine ring substituted on the N-atom in the ring by C 3-7 cycloalkyl.

2. A compound according to claim 1 wherein C 3-7 cycloalkyl is C 5 -cycloalkyl.

3. A compound according to claim 2 having the formula (II)

4. A pharmaceutical composition comprising an effective amount of at least one compound as claimed in claim 1 and a pharmaceutically tolerable excipient.

5. A composition comprising at least (a) a compound of formula (I) as claimed in claim 1 and, (b) a second antiretroviral agent for the simultaneous, separate or sequential use.

6. A composition according to claim 5 wherein the second agent is ritonavir.

7. A composition according to claim 6 wherein the compound of formula II is (1-benzyl-3-{[2-(1-cyclopentyl-piperidin-4-ylamino)-benzothiazole-6-sulfonyl]-isobutyl-amino}-2-hydroxy-propyl)-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester.

8. A method of inhibiting a protease of a multi-drug resistant retrovirus in a mammal infected with said retrovirus comprising administering a protease-inhibiting amount of a compound according to claim 1 to said mammal in need thereof.

9. A method of treating or combating infection or disease associated with multi-drug resistant retrovirus infection in a mammal comprising administering an effective amount of at least one compound according to claim 1 to said mammal.

10. A method of inhibiting multi-drug resistant retroviral replication comprising contacting a retrovirus with an effective amount of at least one compound according to claim 1 .

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2015
From: JANSSEN R & D IRELAND
To: JANSSEN SCIENCES IRELAND UC
Reel/Frame 035496/0382 →
CHANGE OF NAME Recorded May 10, 2012
From: TIBOTEC PHARMACEUTICALS LTD.
To: JANSSEN R&D IRELAND
Reel/Frame 028189/0233 →
CHANGE OF NAME Recorded May 9, 2012
From: TIBOTEC PHARMACEUTICALS LTD.
To: JANSSEN R&D IRELAND
Reel/Frame 028181/0199 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2011
From: DE KOCK, HERMAN AUGUSTINUS; JONCKERS, TIM HUGO MARIA; BOONANTS, PAUL JOZEF GABRIEL MARIA; LAST, STEFAAN JULIEN; DIERYNCK, INGE; BAUMEISTER, JUDITH EVA; VAN'T KLOOSTER, GERBEN ALBERT ELEUTHERIUS
To: TIBOTEC BVBA
Reel/Frame 026155/0032 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2011
From: TIBOTEC BVBA
To: TIBOTEC PHARMACEUTICALS LTD.
Reel/Frame 026155/0156 →